FDA Circular No. 2021-025 was issued last year and has been the guidance for regulatory flexibilities on FDA-issued marketing authorizations considering the pandemic and economic challenges brought by COVID-19.

In the light of the service, the FDA released an amendment of the circular stating that the effectivity is extended from October 01, 2022 until December 31, 2022. Moreover FDA-issued authorization covered by the circular are automatically extended

The following are the FDA-issued authorizations covered by the circular and its amendment.

  • • Licenses to Operate (LTOs)
  • • Certificate of Product Registration / Certificate of Product Notification (CRPs/CPNs)
  • • Local Good Manufacturing Practice (GMP) Certificates
  • • Certificate of GMP Compliance (COCs) for x-ray facilities under the One-Stop Shop Licensing 
  • • System of the Department of Health (DOH)
  • • Certificates of Registration (CORs) for Magnetic Resonance Imaging (MRI) facilities
  • • Special Certification for COVID-19 Test Kits





Guidelines for application of authorization at FDA during pandemic

Effectivity Extension of FDA Regulatory Flexibilities on Pandemic